A unified, connected foundation is transforming the future of digital trials
Bio Pharma Dive
NOVEMBER 21, 2022
A holistic approach allows stakeholders to adapt to the ever-increasing number of clinical trials and data points.
Sat.Nov 19, 2022 - Fri.Nov 25, 2022
289 
AI will continue to attract investment in near future in the healthcare industry
Pharmaceutical Technology
NOVEMBER 25, 2022
Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cause of Alzheimer’s Could Be Coming From Inside Your Mouth
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 22, 2022
In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer’s disease isn’t just a disease, it’s an infection. While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer’s goes way beyond what we used to think.
Bacteria that break down nicotine found in the guts of mice
Medical Xpress
NOVEMBER 24, 2022
A team of researchers affiliated with multiple institutions in China, working with a colleague in the U.S., has isolated a type of bacteria in the guts of mice that break down nicotine. In their paper published in the journal Nature, the group describes how they isolated the bacteria and why their finding could reduce incidences of fatty liver disease in humans.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
FDA approves first gene therapy for hemophilia B
Bio Pharma Dive
NOVEMBER 22, 2022
The treatment, which is for the less common “B” form of the bleeding disorder, will be sold in the U.S. by maker CSL for $3.5 million.
Ozempic compensating for Wegovy’s supply shortage due to high demand
Pharmaceutical Technology
NOVEMBER 25, 2022
In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022. In the meantime, however, Novo Nordisk’s Ozempic, another version of semaglutide indicated particularly for patients with type 2 diabetes, has picked up the slack by being used off-label for obesity patients.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Long-COVID personalized medicine enters Phase 2 trial
BioPharma Reporter
NOVEMBER 22, 2022
GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.
Cancer drugmaker Plexxikon gets new life as Opna Bio
Bio Pharma Dive
NOVEMBER 21, 2022
Eight months after Daiichi Sankyo shuttered the San Francisco Bay Area subsidiary, Plexxikon’s former CEO is resuscitating its drug research under a new name.
NICE questions value and efficacy of five Covid-19 drugs with rejection
Pharmaceutical Technology
NOVEMBER 20, 2022
The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.
Opinion: A tripledemic hurricane is making landfall. We need masks, not just tent hospitals
STAT News
NOVEMBER 22, 2022
A viral hurricane is making landfall on health care systems battered by three pandemic years. With the official start of winter still weeks away, pediatric hospitals are facing crushing caseloads of children sick with RSV and other viral illnesses. Schools that promised a “return to normal” now report widespread absences and even closures from RSV and flu in many parts of the country , contributing to parents missing work in record numbers.
Commercial Drug Sourcing for Clinical Trials
Advertisement
The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Sponsors can face a number of challenges when trying to obtain these critical supplies for their studies, including addressing product lead times, availability, expiry limitations, safety and cost, among others. Choosing the right partner with global sourcing, regulatory, quality and clinical packaging expertise can provide the necessary guidance to help sponsors
Brain cancer vaccine succeeds at prolonging survival in Phase 3 trial
BioPharma Reporter
NOVEMBER 21, 2022
A Phase 3 trial for Northwest Biotherapeuticsâs DCVax-L vaccine extended survival in patients with gliobastoma for many months, or in some cases, years: according to new data.
GSK to pull blood cancer drug from US market after study failure
Bio Pharma Dive
NOVEMBER 22, 2022
The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.
Umoja and IASO partner to develop therapies for haematological malignancies
Pharmaceutical Technology
NOVEMBER 22, 2022
Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. Under the alliance, the companies will assess the induced cytotoxic innate lymphocytes (iCIL) platform of Umoja with chimeric antigen receptors (CARs) of IASO to develop the next generation of widely accessible, easily available cell therapies.
Hidden audits reveal millions in overcharges by Medicare Advantage plans
NPR Health - Shots
NOVEMBER 21, 2022
Taxpayers footed the bill for care that should have cost far less, according to records released under the Freedom of Information Act. The U.S. government may charge insurers $650 million as a result.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Wireless smart bandage provides new insights on healing chronic wounds
Medical Xpress
NOVEMBER 24, 2022
Some wounds just won't heal. Infections, diseases like diabetes, and suppressed immune systems often stack up to slow healing. Chronic wounds can last months and lead to anxiety and depression. In the worst cases, they are life threatening. Cost of treatment has soared to $25 billion each year.
Teva taps Sandoz veteran to take over CEO post from Schultz
Bio Pharma Dive
NOVEMBER 21, 2022
Richard Francis will take over for the retiring Kåre Schultz on Jan. 1. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt.
FDA grants approval for CSL’s haemophilia B gene therapy
Pharmaceutical Technology
NOVEMBER 23, 2022
The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients. The treatment is indicated for usage in such individuals who use Factor IX prophylaxis treatment, or have an existing or historical life-threatening haemorrhage, or recurrent, serious episodes of sudden bleeding.
Experts are concerned Thanksgiving gatherings could accelerate a 'tripledemic'
NPR Health - Shots
NOVEMBER 22, 2022
As the holiday approaches, infectious disease specialists are bracing for the possibility that big family get-togethers and travel will propel the spread of RSV, flu and COVID-19.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
New male contraceptive does not involve hormones
Medical Xpress
NOVEMBER 24, 2022
A team of researchers at a company called Contraline has developed a new kind of male contraceptive. Instead of using hormones to disrupt sperm production, the new technique involves placing a hydrogel called ADAM into the vas deferens to prevent sperm from making its way to the urethra. The new technique is not yet available for men seeking an alternative way to prevent pregnancy, however—it is currently undergoing a clinical trial in Australia.
Merck to buy blood cancer biotech Imago for $1.35B
Bio Pharma Dive
NOVEMBER 21, 2022
The deal is Merck’s second notable acquisition of a cancer drugmaker in the past year and a half, part of a strategy to diversify its pipeline beyond top-selling immunotherapy Keytruda.
Japan’s MHLW approves Daiichi Sankyo’s breast cancer treatment
Pharmaceutical Technology
NOVEMBER 25, 2022
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults. The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane. The latest development was based on the findings from the international, head-to-head, open-label, randomised Phase III DESTINY-Breast03 trial which analysed the efficacy a
How monoclonal antibodies lost the fight with new COVID variants
NPR Health - Shots
NOVEMBER 20, 2022
The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.
Real-world data show updated Covid-19 boosters increase protection against infection
STAT News
NOVEMBER 22, 2022
The updated Covid-19 boosters increase people’s protection against symptomatic infection from the coronavirus, according to some of the first estimates of how the shot is performing in the real world and in people, not just in lab experiments. What’s more, that protection was even stronger when people waited a longer period of time since their last dose of the original shot.
The next era of Greater Boston’s biotech boom
Bio Pharma Dive
NOVEMBER 22, 2022
Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs.
XtalPi and CK Life Sciences to develop AI-driven tumour vaccine R&D platform
Pharmaceutical Technology
NOVEMBER 25, 2022
XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform. Such a platform will aid in boosting tumour vaccine discovery and design expertise as well as expedite the development of other kinds of vaccines.
Doctors who want to defy abortion laws say it's too risky
NPR Health - Shots
NOVEMBER 23, 2022
In states with abortion bans, doctors may hesitate to provide abortion care in a medical emergency. Some ethicists argue doctors should practice civil disobedience and put patients' lives first.
Making the Case for Case Management for Cell and Gene Therapies
Advertisement
As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements. Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.
STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B
STAT News
NOVEMBER 22, 2022
The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder. The one-time treatment, called Hemgenix, was developed by the Dutch biotech company UniQure and will be marketed by CSL Behring, an Australian pharmaceutical company.
How brands can tap into wellness – lessons from influencers
Bio Pharma Dive
NOVEMBER 21, 2022
Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry sectors.
Japan grants emergency regulatory approval for Shionogi’s Covid-19 drug
Pharmaceutical Technology
NOVEMBER 22, 2022
The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted emergency regulatory approval for Shionogi ’s new anti-SARS-CoV-2 drug, Xocova (ensitrelvir fumaric acid, S-217622), for Covid-19. This approval under the emergency regulatory approval system is granted under the Article 14-2-2 of the Pharmaceuticals and Medical Devices Act, the company noted.
'Sunny Makes Money': India installs a record volume of solar power in 2022
NPR Health - Shots
NOVEMBER 21, 2022
India, on track to become the world's most populous country, gets about 70% of its electricity from coal. But the government is aggressively investing in renewable energy — particularly solar.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Let's personalize your content